Pfizer Gets FDA Panel’s Backing in RSV Vaccine Race

A panel of outside advisers to the US health regulator recommended Pfizer Inc's respiratory syncytial virus vaccine, bringing it closer to becoming one of the first approved RSV shots for older adults in the United States.
Reuters Health Information
A panel of outside advisers to the US health regulator recommended Pfizer Inc’s respiratory syncytial virus vaccine, bringing it closer to becoming one of the first approved RSV shots for older adults in the United States.
Reuters Health Information